Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock
Chardan has initiated coverage on EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and a price target of $21 based on the company's commercial potential with its lead EYP-1901 for Wet Age-related macular degeneration (AMD).
The price target represents an upside of over 160%.
The lead program utilizes a bioerodible Durasert formulation. Durasert technology is a micro-implant that can be injected intravitreally in an office setting.
Related: EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss.
Once injected, it releases a therapeutic at a controlled rate over an extended period, from weeks to months.
Chardan writes that Durasert technology is well-validated, with four products approved to date.
Durasert provides for zero-order release kinetics, meaning that vorolanib is released at a nearly constant rate over the implant's life.
Price Action: EYPT shares are up 2.37% at $7.98 during the market session on the last check Thursday.
Latest Ratings for EYPT
Date | Firm | Action | From | To |
---|---|---|---|---|
Nov 2021 | HC Wainwright & Co. | Maintains | Buy | |
May 2021 | HC Wainwright & Co. | Maintains | Buy | |
Jan 2021 | Cantor Fitzgerald | Initiates Coverage On | Overweight |
View More Analyst Ratings for EYPT
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.